Bayer Aktiengesellschaft (ETR:BAYN)
37.47
-0.31 (-0.81%)
Mar 6, 2026, 10:15 AM CET
Bayer Aktiengesellschaft Revenue
In the year 2025, Bayer Aktiengesellschaft had annual revenue of 45.58B EUR, down -2.21%. Bayer Aktiengesellschaft had revenue of 11.44B in the quarter ending December 31, 2025, a decrease of -2.48%.
Revenue
45.58B
Revenue Growth
-2.21%
P/S Ratio
0.81
Revenue / Employee
514.96K
Employees
88,502
Market Cap
37.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 45.58B | -1.03B | -2.21% |
| Dec 31, 2024 | 46.61B | -1.03B | -2.16% |
| Dec 31, 2023 | 47.64B | -3.10B | -6.11% |
| Dec 31, 2022 | 50.74B | 6.66B | 15.10% |
| Dec 31, 2021 | 44.08B | 2.68B | 6.48% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck KGaA | 21.27B |
| Siemens Healthineers AG | 23.30B |
| Fresenius SE & Co. KGaA | 22.45B |
| Sartorius Aktiengesellschaft | 3.54B |
| Fresenius Medical Care AG | 19.63B |
| Ottobock SE & Co. KGaA | 1.66B |
| Fielmann Group AG | 2.42B |
| Carl Zeiss Meditec AG | 2.20B |
Bayer Aktiengesellschaft News
- 1 day ago - Bayer Aktiengesellschaft (BAYRY) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Bayer's $7.25 billion Roundup settlement gets initial OK from Missouri judge - Reuters
- 1 day ago - New FDA 510(k) Clearance Expands Bayer's MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments - Business Wire
- 2 days ago - Bayer Net Loss Widens on Weedkiller Litigation Charges - WSJ
- 6 days ago - Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer - Business Wire
- 7 days ago - Bayer's XOFIGO® (radium-223 dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases - Business Wire
- 8 days ago - Some roundup plaintiffs seek to delay preliminary approval of proposed $7.25 bln bayer settlement, court filing shows - Reuters
- 10 days ago - Bayer files lawsuit against Johnson & Johnson, Janssen Biotech - Reuters